Vaccine Infrastructure as Strategic Asset

Vaccine breakthroughs in the 2020s are not accidental but the output of layered infrastructure—genomics, structural biology, cell manufacturing, distribution networks, and regulatory throughput—that governments and industry together created over decades. Treating that stack as a strategic public asset reframes vaccine policy from ad‑hoc R&D funding to long‑term industrial and data governance (secure scaleable biomanufacturing, national sequencing and distribution capacity). — If states underinvest or cede this infrastructure to a handful of private or foreign actors, they risk losing rapid response capacity for future pandemics and the industrial benefits of platform biology.